Program Description
Anemia is a common complication of myeloid disorders such as myelofibrosis (MF) and myelodysplastic syndromes (MDS) that can lead to fatigue, increased need for red blood cell transfusions, and iron overload. Oncology pharmacists play a vital role in delivering effective management strategies to resolve anemia in myeloid disorders, particularly through the use of novel therapies. This program will delve into the multifaceted causes and consequences of anemia in MDS and MF, including the burden of transfusion-dependent anemia. The treatment landscape for anemia in myeloid disorders is rapidly expanding, and the discussion will explore the historical challenges of anemia management as well as emerging therapeutic strategies and related mechanisms of action, efficacy data from key clinical trials, and the current role of emerging therapies in the treatment paradigm. Oncology pharmacists will review practical guidance on supportive care, dose adjustments, and toxicity management for these emerging therapies to optimize anemia management.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: September 22, 2025
Expiration date: September 22, 2026
Time to complete activity: 1.0 hours
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the key mechanisms underlying anemia in myelofibrosis (MF) and myelodysplastic syndromes (MDS) to strengthen pharmacists' understanding of emerging therapeutic strategies
- Explore the clinical applications of novel therapies for anemia in MF and MDS, focusing on how these strategies enhance patient care and outcomes compared with historical approaches
- Employ appropriate dose adjustments and supportive care measures to enhance treatment outcomes for anemia in myeloid disorders
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here